[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100465574":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":30,"responsibleParty":47,"collaborators":10,"id":49,"slug":10,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":10,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":10,"enrollmentInfo":57,"targetDuration":10,"studyType":60,"phases":10,"briefSummary":61,"conditions":62,"keywords":10,"overallStatus":33,"whyStopped":10,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"Otsuka Pharmaceutical Co., Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Drug",null,"Ajovy syringe for SC injection 225 mg.",[13],"Drug: Fremanezumab 225 Mg\u002F1.5 mL Subcutaneous Solution",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","Fremanezumab 225 Mg\u002F1.5 mL Subcutaneous Solution","The usual adult dose is 225 mg of fremanezumab (genetical recombination) administered subcutaneously as a single dose once every 4 weeks or 675 mg administered subcutaneously as a single dose once every 12 weeks.",[9],[21],{"name":22,"affiliation":5,"role":23},"Yasuhiko Fukuta, PhD","STUDY_DIRECTOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Pharmacovigilance Department Otsuka Pharmaceutical Co., Ltd","CONTACT","+81-6-6943-7722","komaniwa.satoshi@otsuka.jp",[31],{"facility":32,"status":33,"city":34,"state":10,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Pharmacovigilance Department","RECRUITING","Osaka","540-0021","Japan","JP",{"type":39,"coordinates":40},"Point",[41,42],135.50107,34.69379,{"lat":42,"lon":41},[45],{"name":46,"role":27,"phone":10,"phoneExt":10,"email":10},"Satoshi Komaniwa, PhD",{"type":48,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100465574",false,"NCT05342493","Specified Drug Use Survey on AJOVY Subcutaneous Injection for Long-term Use","AJOVY Subcutaneous Injection Long-term Specified Use-results Survey","Inclusion Criteria:\n\n\\-\n\nExclusion Criteria:\n\n* patients with a known hypersensitivity to components of AJOVY","ALL","18 Years",{"count":58,"type":59},1000,"ESTIMATED","OBSERVATIONAL","To evaluate the long-term safety of AJOVY in patients under actual use conditions and to specifically evaluate cardiovascular events. In addition, information on efficacy will be collected.",[63],"Migraine Disorders","2026-06-17",{"date":66,"type":67},"2026-06-22","ACTUAL",{"date":69,"type":67},"2022-04-20",{"date":71,"type":59},"2029-06-22",{"name":5,"class":6},1]